Abstract

DNA mismatch repair (MMR) genes play an important role in maintaining genome stability. Germline mutations in MMR genes disrupt the mismatch repair function and cause genome instability. Carriers with MMR germline mutations are more likely to have MMR deficiency and microsatellite instability (MSI) than non-carriers and are prone to develop colorectal cancer (CRC) and extracolorectal malignancies, known as Lynch syndrome (LS). MMR gene testing for suspected mutation carriers is a reliable method to identify the mutation types and to discover mutation carriers. Given that carriers of MMR germline mutations have a higher risk of LS-related cancers (LS-RC) and a younger age at onset than non-carriers, early surveillance and regular screening of relevant organs of carriers are very important for early detection of related cancers. This review mainly focuses on the general status of MMR carriers, the approaches for early detection and screening, and the surveillance of MMR mutation carriers in China. Population screening of MMR germline mutation carriers in China will be helpful for early detection, early diagnosis and treatment of MMR mutation carriers, which may improve the 5-year survival, and reduce mortality and incidence rate in the long term.

Highlights

  • DNA mismatch repair (MMR) genes play an important role in maintaining genome stability

  • Population screening for carries with MMR mutation has important clinical implications for Lynch syndrome (LS)-related cancers (LS-RC), such as improving 5-year survival, reducing the mortality, and reducing the incidence in the long-term

  • MMR gene testing is considered as the gold method for finding out MMR mutation carriers worldwide [15]

Read more

Summary

Introduction

DNA mismatch repair (MMR) genes play an important role in maintaining genome stability. The average cumulative risk of LS-RC in MLH1 and MSH2 mutation carriers was 9.7 %, 38.9 %, 69.5 %, 92.4 %, CRC was 9.7 %, 36.4 %, 66.7 %, 81.3 %, and gastric cancer was 0, 1.4 %, 6.1 %, 29.6 %, at age 30, 40, 50, 60 years old, respectively [20]. MMR gene testing is considered as the gold method for finding out MMR mutation carriers worldwide [15] This high-cost technology has not yet been fully transformed into clinical applications in China. The sensitivity and specificity of combined IHC and MSI detection approach reached 100 and 72.4 %, respectively for screening LS-Table 1 The risk, age at diagnosis, regular screening method, starting age for surveillance, and survival of MMR mutation carriers

49 MSH6: 54 PMS2
Findings
Conclusions and future perspectives
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call